Although offered now by AbbVie and Janssen, the drug was originated by researchers at Pharmacyclics (obtained by AbbVie in 2015) and Celera Genomics, who initially evaluated it in mouse types of arthritis prior to shifting to focus on hematological malignancies. The plasma concentration of dotinurad improved in a dose-dependent fashion https://hannesd075txa8.yomoblog.com/profile